Selpercatinib

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Selpercatinib
Jan 1, 2025, 08:59 | Blog
Oncology Brothers: 6 new drugs in Skin Cancer, Thyroid Cancer, Sarcoma and Glioma by U.S. FDA
Oncology Brothers shared a post on X: "2024 approvals: Summary of 6 new drugs/indications in…
Dec 23, 2024, 12:47 | Science
Giuseppe Banna: Selpercatinib for RET fusion+ NSCLC by Benjamin Besse et al.
A recent paper by Benjamin Besse, Director of Clinical Research at the Gustave Roussy Institute,…
Oct 4, 2024, 15:19 | Blog
Tanja Obradovic: FDA granted approval to selpercatinib for advanced or metastatic medullary thyroid cancer with a RET mutation
Tanja Obradovic shared a post on LinkedIn: "Outstanding news for patients with metastatic medulary thyroid…
Jul 14, 2024, 06:07 | Blog
Shahrin Ahmed: The FDA has approved Selpercatinib for treating RET-linked thyroid cancer
Shahrin Ahmed, Medical specialist at Canadian Cancer Society, shared on X: "The FDA has approved Selpercatinib…
Jun 15, 2024, 14:10 | Drugs
Vivek Subbiah: FDA granted full traditional approval of RET inhibitor Selpercatinib in RET+ thyroid cancers
Vivek Subbiah shared on LinkedIn:             . "FDA granted full traditional…
Apr 14, 2024, 11:39 | Drugs
Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs
Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter: "FDA…
Apr 9, 2024, 09:03 | Insight
Giannis Mountzios: The value of post-marketing pragmatic re-assessment of new TKIs in NSCLC
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Mar 19, 2024, 03:22 | Blog
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah shared a post on X/Twitter: ''Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic…
Mar 16, 2024, 10:45 | Drugs
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah recently shared a post on X/Twitter: “Exceptional Responses to Selpercatinib in RET Fusion–Driven…
Dec 4, 2023, 15:54 | Blog
Vivek Subbiah: Tissue-agnostic precision medicine takes the spotlight!
Vivek Subbiah shared a post on his LinkedIn page: "Hot off the press- Friday Motivation!…
Nov 28, 2023, 16:43 | Drugs
Vivek Subbiah: Pleased to share our review on RET inhibitors
Vivek Subbiah shared on LinkedIn: "Pleased to share our review on RET inhibitors and RET inhibitor…
Aug 25, 2023, 16:32 | Insight
Vivek Subbiah: Huge win for patients with RET+ thyroid cancers.
Quoting Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute,…
All: 12 Posts: 1 - 100
Special Coverage